Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections

A C2-C4, C1-C4 technology, applied in the field of preparing the compound, can solve the problems of high cost and limited curative effect

Active Publication Date: 2016-08-24
GILEAD SCI INC
View PDF37 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The monoclonal antibody palivizumab is available for immunoprophylaxis, but its use is limited to high-risk infants, eg, premature infants or those with congenital heart or lung disease, and is often cost prohibitive for general use
In addition, the nucleoside analog ribavirin has been approved as the only antiviral agent for the treatment of HRSV infection with limited efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections
  • Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections
  • Pyrrolo [1,2,f] [1,2,4] triazines useful for treating respiratory syncitial virus infections

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0343] Example 1-(2R,3S,4R,5S)-5-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-3,4-dihydroxy -2-(Hydroxymethyl)tetrahydrofuran-2-carbonitrile.

[0344] To a solution of crude intermediate lo in methanol (1 mL) was added methylamine (40% in water, 0.3 mL) at room temperature. After 2.5 hours, the reaction mixture was concentrated under reduced pressure and analyzed by preparative HPLC (Phenominex Luna 5u C18 100 x 30 mm column, 5-15% acetonitrile / water gradient, 25 min) for direct purification. Fractions containing the desired product and the 4' anomer were combined and concentrated under reduced pressure. Then by preparative HPLC (Phenominex Luna 5u C18 100 x 30 mm column, 5-15% acetonitrile / water gradient, 25 min) to separate the 4' anomer. Fractions containing the desired product were combined and lyophilized to give Example 1.

[0345] 1 H NMR (400MHz, CD 3 OD)δ7.79(s,1H),6.85(d,J=4.5Hz,1H),6.76(d,J=4.5Hz,1H),5.45(d,J=5.9Hz,1H),4.59(t , J=5.7Hz, 1H), 4.40 (d, J=...

Embodiment 3

[0476] Example 3-(2R,3R,4R,5S)-5-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-4-fluoro-3- Hydroxy-2-(hydroxymethyl)tetrahydrofuran-2-carbonitrile.

[0477] at 0°C and N 2 To a solution of intermediate 3d (100 mg, 0.191 mmol) / THF (2 mL) in a polypropylene tube was added 70% HF·pyridine / pyridine (60 μL, 0.478 mmol) under atmosphere. The reaction was checked after 20 minutes; no reaction so additional 70% HF·pyridine / pyridine (150 μL) was added and the cooling bath removed. After 1 h 50 min additional 70% HF·pyridine / pyridine (150 μL) was added. Additional 70% HF-pyridine / pyridine (300 [mu]L) was added after a further 2 hours. Additional 70% HF-pyridine / pyridine (1 mL) was added after a further 2 hours and 15 minutes. The reaction became clear and homogeneous on this last addition of 70% HF·pyridine / pyridine. The reaction was stirred overnight. The next day the reaction was complete. Cool the reaction in an ice bath and wash with H 2 O and a small amount of saturated NaHCO ...

Embodiment 4

[0555] Example 4-(2R,3S,4R,5S)-5-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-2-(hydroxymethyl )-2-Methyltetrahydrofuran-3,4-diol

[0556] Intermediate 4r (23 mg, 0.042 mmol) was dissolved in formic acid / MeOH solution (1:9, 10 mL). Palladium black was added and stirred at 60°C for 90 minutes. Cool to room temperature and filter through celite. The filtrate was concentrated under reduced pressure. Purified by preparative HPLC. Concentrate under reduced pressure. dissolved in NaHCO 3(水溶液) and purified by HPLC under neutral conditions to obtain Example 4.

[0557] Prep HPLC system: Gilson 215 Liquid Handler; Phenomenex Gemini, C 18 4u, 100x30.0mm

[0558] Buffer A: 0.1% TFA / water; Buffer B: 0.1% TFA / acetonitrile; 5-100% Buffer B for 13 minutes, 20 mL / min.

[0559] 1 H NMR (400MHz, CDCl 3 ):δ8.01(s,1H),7.41(d,J=4.8Hz,1H),7.02(d,J=4.8Hz,1H),5.33(d,J=8Hz,1H),4.53-4.49( m, 1H), 4.15 (d, J=5.6Hz, 1H), 3.50 (m, 2H), 1.27 (s, 3H).

[0560] LC / MS: t R =0.30min, MS m / z=281.3[M...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein are formulations, methods and substituted tetrahydrofuranyl- pyrrolo[1,2-f][1,2,4]triazine-4-amine compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of tetrahydrofuranyl-pyrrolo[1,2-fj[i,2,4]triazine-4-amine compounds.

Description

technical field [0001] Provided herein are substituted tetrahydrofuranyl-pyrrolo[1,2-f][1,2,4]triazine- 4-Amine compounds, processes and pharmaceutical formulations, and processes and intermediates useful in the preparation of said compounds. Background technique [0002] Pneumovirinae viruses are negative-sense, single-stranded RNA viruses that are responsible for many prevalent human and animal diseases. The pneumovirinae subfamily of viruses is part of the Paramyxoviridae family and includes the human respiratory syncytial virus (HRSV). Almost all children experience HRSV infection by their second birthday. HRSV is a leading cause of lower respiratory tract infections in infants and children, with 0.5% to 2% of those infected requiring hospitalization. Older adults and adults with chronic heart disease, lung disease, or those who are immunosuppressed are also at high risk for developing severe HRSV disease (http: / / www.cdc.gov / rsv / index.html). There is currently no vac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/706A61K31/16C07D487/04
CPCA61K31/706C07D487/04A61K31/16A61P31/14A61P31/16C07D405/14C07D405/04C07H7/06C07F9/6561A61K31/407A61K31/53
Inventor M·O·H·科拉克E·多伊尔弗勒R·L·马克曼D·塞吉尔
Owner GILEAD SCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com